Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Renal Cell

Kidney Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Bristol-Myers Squibb

This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.

Study of Nivolumab for Advanced Cancers in India

Safety Study of Nivolumab for Selected Advanced Malignancies in India

Number of participants with treatment-related Adverse Events based on worst ctc grade

Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

Number of participants with treatment-related Select Adverse Events based on worst ctc grade for the following categories:

Pulmonary, Gastrointestinal, Endocrinopathies, Hepatic, Renal, Skin, Neurological and Hypersensitivity/Infusion reactions

Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

Number of participants with treatment-related Serious Adverse Events based on worst CTC grade

Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

Number of participants with Adverse events leading to discontinuation of treatment based on worst CTC grade

Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

Includes events reported between first dose and 100 days after last dose of Nivolumab or for a total of 26 weeks from first on-study treatment with Nivolumab whichever is earliest.

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Bristol-Myers Squibb Study Director

Any Grade

Grade 3-4

Grade 5

Number of Participants With Treatment-related Adverse Events

Pulmonary (Grade 3)

Pulmonary (Grade 5)

Hepatic (Grade 1)

Skin (Grade 1)

Hypersensitivity/Infusion reaction (Grade 1)

Hypersensitivity/Infusion reaction (Grade 2)

Number of Participants With Treatment-related Select Adverse Events

Grade 3 - 4

Number of Participants With Treatment-related Serious Adverse Events

Grade 1

Grade 2

Grade 3

Grade 4

Number of Participants With Adverse Events Leading to Discontinuation

Overall Study

Spots Global Cancer Trial Database for Study of Nivolumab for Advanced Cancers in India

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial